JPH07504203A - - Google Patents

Info

Publication number
JPH07504203A
JPH07504203A JP50825294A JP50825294A JPH07504203A JP H07504203 A JPH07504203 A JP H07504203A JP 50825294 A JP50825294 A JP 50825294A JP 50825294 A JP50825294 A JP 50825294A JP H07504203 A JPH07504203 A JP H07504203A
Authority
JP
Grant status
Application
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50825294A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
JP50825294A 1992-09-15 1993-09-14 Pending JPH07504203A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US94623692 true 1992-09-15 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (1)

Publication Number Publication Date
JPH07504203A true true JPH07504203A (en) 1995-05-11

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50825294A Pending JPH07504203A (en) 1992-09-15 1993-09-14

Country Status (5)

Country Link
EP (1) EP0620739A4 (en)
JP (1) JPH07504203A (en)
KR (1) KR100232688B1 (en)
CA (1) CA2123593C (en)
WO (1) WO1994006476A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534375A (en) * 1998-12-30 2002-10-15 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Activity inhibition
JP2003501043A (en) * 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション In tumor necrosis factor (tnf) related disorders, methods and compositions for reducing the level of tnf
JP2006500927A (en) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド Gene expression system based on codon translational efficiency
JP2006512900A (en) * 2002-08-16 2006-04-20 インペリアル カレッジ イノベーションズ リミテッド Therapeutic compositions of Rage related diseases and methods
JP2007084558A (en) * 1998-10-23 2007-04-05 Amgen Modified peptide as therapeutic agent
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
JPWO2005035586A1 (en) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Fusion protein composition
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification of Fc- fusion protein

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
ES2197149T3 (en) * 1992-03-30 2004-01-01 Immunex Corporation Fusion proteins comprising two receptors for tumor necrosis factor.
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2290021A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
EP1097165A4 (en) * 1998-07-13 2001-09-12 Parkash S Gill Novel inhibitors of angiogenesis and tumor growth
EP1206275B1 (en) * 1998-11-05 2007-09-05 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165116A1 (en) * 1999-04-02 2002-01-02 Immunex Corporation Use of soluble tumor necrosis factor receptor for treating heart failure
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
JP2003533986A (en) 2000-05-04 2003-11-18 エイブイアイ バイオファーマ, インコーポレイテッド Splice regions antisense compositions and methods
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
DE602004013557D1 (en) * 2003-02-28 2008-06-19 Ares Trading Sa LIQUID FORMULATIONS OF TUMORNEKROSEFRAKTOR binding protein TBP-1
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006053301A3 (en) * 2004-11-12 2007-04-05 Xencor Inc Fc variants with altered binding to fcrn
EP2089521A1 (en) * 2006-02-08 2009-08-19 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7863426B2 (en) 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008005315A8 (en) 2006-06-30 2009-01-15 Abbott Biotech Ltd Automatic injection device
JP2010501623A (en) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification of Fc-containing protein
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNF-alpha INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008154543A3 (en) 2007-06-11 2009-04-23 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
US8636704B2 (en) 2009-04-29 2014-01-28 Abbvie Biotechnology Ltd Automatic injection device
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
RU2573042C2 (en) 2010-04-21 2016-01-20 Эббви Байотекнолоджи Лтд. Worn device for automatic injection for controlled supply of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
ES2685607T3 (en) 2010-06-03 2018-10-10 Abbvie Biotechnology Ltd Uses and compositions for treating hidradenitis suppurativa (HS)
FR2962335B1 (en) 2010-07-12 2013-01-18 Cll Pharma Using the nonapeptide pat in the treatment and prevention of neurodegenerative diseases
WO2012019099A9 (en) 2010-08-05 2012-07-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
ES2637979T3 (en) 2011-01-24 2017-10-18 Abbvie Biotechnology Ltd Automatic injection devices overmolded grip surfaces
US9956353B2 (en) 2011-03-29 2018-05-01 Abbvie Inc. Shroud deployment in automatic injection devices
CN107096098A (en) 2011-04-21 2017-08-29 艾伯维公司 Wearable automatic injection device
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR101525919B1 (en) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 Bispecific antibody based on TNFR2 for preventing and traeating autoimmune disease
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2065346C (en) * 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007084558A (en) * 1998-10-23 2007-04-05 Amgen Modified peptide as therapeutic agent
JP2002534375A (en) * 1998-12-30 2002-10-15 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Activity inhibition
JP2003501043A (en) * 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション In tumor necrosis factor (tnf) related disorders, methods and compositions for reducing the level of tnf
US7670602B2 (en) 2001-07-26 2010-03-02 Medexgen Co., Ltd Concatameric immunoadhesion molecule
US8372961B2 (en) 2001-07-26 2013-02-12 Medexgen Co., Ltd. Polynucleotides encoding concatameric immunoadhesion molecules
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
JP2006512900A (en) * 2002-08-16 2006-04-20 インペリアル カレッジ イノベーションズ リミテッド Therapeutic compositions of Rage related diseases and methods
JP2006500927A (en) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド Gene expression system based on codon translational efficiency
JPWO2005035586A1 (en) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Fusion protein composition
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification of Fc- fusion protein

Also Published As

Publication number Publication date Type
KR100232688B1 (en) 1999-12-01 grant
EP0620739A4 (en) 1997-01-15 application
EP0620739A1 (en) 1994-10-26 application
WO1994006476A1 (en) 1994-03-31 application
CA2123593A1 (en) 1994-03-31 application
CA2123593C (en) 2000-03-14 grant

Similar Documents

Publication Publication Date Title
DE9203384U1 (en)
DE9200614U1 (en)
DE9202439U1 (en)
DE9202983U1 (en)
DE9202374U1 (en)
DE9202463U1 (en)
DE9200468U1 (en)
DE9200330U1 (en)
DE9200349U1 (en)
DE9201136U1 (en)
DE9202893U1 (en)
DE9202883U1 (en)
DE9200303U1 (en)
DE9201042U1 (en)
DE9201081U1 (en)
DE9200201U1 (en)
DE9200986U1 (en)
DE9201752U1 (en)
DE9200317U1 (en)
DE9202198U1 (en)
DE9202522U1 (en)
DE9200769U1 (en)